V8 Peptides — Engineered Performance
Research Library
CJC-1295 DAC vs No DAC: Which Form Fits the Assay?
CJC-1295 DACComparison

CJC-1295 DAC vs No DAC: Which Form Fits the Assay?

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What separates CJC-1295 with DAC from CJC-1295 without DAC? The DAC form carries a lysine-linked maleimide group that attaches covalently to serum albumin, so in rats it stayed in plasma beyond 72 hours; the no-DAC form (modified GRF 1-29) has no such group and gives a short, pulse-like signal. The choice follows the assay: sustained exposure designs suit the DAC molecule, pulse and recovery designs suit the no-DAC molecule. V8 lists the no-DAC peptide for laboratory research use only; the calculator handles concentration arithmetic.

The two names are used almost interchangeably online, which causes real experimental errors: a design that assumes a short signal is run with a long-acting molecule, or the reverse. This article does not repeat the head-to-head table in the DAC versus no-DAC comparison. It organizes the choice around the assay, and it reports what the primary rodent papers measured so that duration claims have a source. For laboratory research use only; not for human consumption.

One backbone, one added group

Both forms derive from the first 29 residues of growth-hormone-releasing hormone, the shortest fragment that keeps full receptor activity (Guillemin and colleagues, 1982; Rivier and colleagues, 1982). The native fragment is cleaved at its N-terminus by plasma dipeptidyl peptidase, which in human plasma converts GRH(1-44) to an inactive GRH(3-44) product (Frohman and colleagues, 1986). Substituting D-alanine at position 2 protects against that cleavage. The DAC variant then adds, at the C-terminus, a lysine bearing a maleimidopropionamide group that reacts with the free thiol of cysteine 34 on albumin (Jetté and colleagues, 2005). The no-DAC variant stops after the substituted 29-mer.

PropertyCJC-1295 with DACCJC-1295 without DAC
BackboneTetrasubstituted GRF(1-29)Modified GRF(1-29)
Extra groupC-terminal lysine with maleimide linkerNone
Albumin bindingCovalent, to Cys34None
Plasma presence in ratsBeyond 72 h reportedShort; minutes to tens of minutes in animal models
Typical use in assay designSustained receptor exposurePulse, decay and recovery designs

Product facts for the no-DAC peptide (formula C152H252N44O42, ≥98% HPLC purity, lyophilized powder in 5 mg and 10 mg vials) are on the CJC-1295 (No DAC) page.

What the primary rodent papers actually measured

Jetté and colleagues (2005) synthesized three maleimido derivatives of hGRF(1-29), bioconjugated them to human serum albumin ex vivo, and found enhanced stability against dipeptidyl peptidase IV and activity in a GH secretion assay in cultured rat anterior pituitary cells. In normal male Sprague Dawley rats given subcutaneously, the best compound (CJC-1295) produced a 4-fold increase in GH area under the curve over 2 hours compared with hGRF(1-29). It was present in plasma beyond 72 hours, and a Western blot showed a species on the albumin band that appeared after 15 minutes and persisted beyond 24 hours.

Alba and colleagues (2006) used one-week-old GHRH knockout mice, exposed for five weeks with 2 µg of CJC-1295 at 24-, 48- or 72-hour intervals. Animals receiving it every 24 hours had normal body weight and length; the 48- and 72-hour groups improved without full normalization. The compound increased total pituitary RNA and GH mRNA, which the authors interpreted, with immunohistochemistry, as somatotroph proliferation. The authors’ introduction notes that even twice-daily administration of a short GHRH analog had been unable to normalize growth in the same knockout (Alba and colleagues, 2006).

These are the sources behind the duration claim. They describe the DAC compound; they say nothing about the no-DAC peptide beyond the comparison implied by the unconjugated hGRF(1-29) arm in the first paper.

Why pulsatility matters to the choice

Endogenous GH secretion is episodic. Clark and Robinson (1985) found in rats that pulsatile intravenous infusions of GRF(1-29)NH2 accelerated growth and raised pituitary GH content, whereas continuous infusion at the same daily amount was ineffective. That result is the classical argument that the pattern of exposure, and not only its total, shapes the response. Reviews of GH neuroregulation describe the same dependence on timing relative to somatostatin tone (Giustina and Veldhuis, 1998).

For assay design the implication is direct. A long-acting molecule delivers prolonged receptor engagement and cannot be washed out within a short experiment; a short-acting one allows an experimenter to impose a pattern. Neither is superior in the abstract.

Matching form to assay

Assay designFitReasoning
Pulse-and-recovery in perifused pituitary cellsNo-DACSignal can be applied and removed within the time course
Receptor desensitization and resensitization kineticsNo-DACClean on/off exposure allows the recovery phase to be observed
Chronic exposure in a long animal studyDACProlonged plasma presence reduces the number of administrations in the design
Studies on albumin-conjugation chemistry or half-life extensionDACThe conjugate is the object of study
Combination with a ghrelin-receptor agonist to study pulsesNo-DACShort signals keep the interaction interpretable
Short cell-culture signaling assays (cAMP)Either; no-DAC simplerAlbumin in the medium may bind the DAC form and change free concentration

For combination designs with a secretagogue, see CJC-1295 and ipamorelin research overview; the DAC compound is introduced in the DAC research overview.

Practical differences at the bench

Solutions of both forms are handled as peptide solutions: cold storage, no shaking, minimal freeze–thaw. The DAC form adds a reactive maleimide whose stability in aqueous solution is itself a variable, so it should not be left in solution longer than needed. The no-DAC peptide has no such group. Each is a lyophilized powder when supplied, and a protocol for dissolving it is in how to reconstitute a lyophilized peptide. Concentration is mass divided by diluent volume for both.

If albumin is present in the medium, as in serum-containing culture, a DAC molecule can attach to it, so nominal and free concentrations diverge. Serum-free conditions simplify interpretation. The no-DAC peptide is more exposed to peptidases in serum, an issue for any long incubation. Report the medium composition either way.

Reading the literature without confusing the two

Many papers and most online summaries say “CJC-1295” without qualification. The first paper in the field defines CJC-1295 as the DAC molecule (Jetté and colleagues, 2005). The modified GRF(1-29) compound is the older backbone without the linker. When a source reports a duration of days, it describes the DAC form; when it reports short pulses, it describes an unconjugated analog. A claim about duration without a stated form should not be carried into a methods section. The history is traced in the CJC-1295 No DAC research overview, and analytical checks for the supplied peptide are in CJC-1295 No DAC purity testing.

Frequently asked questions

What is the difference between CJC-1295 with DAC and without DAC?

The DAC form has a C-terminal lysine carrying a maleimide group that attaches covalently to serum albumin, extending its time in plasma. The no-DAC form lacks that group and behaves as a short-acting modified GRF(1-29).

How long did CJC-1295 with DAC stay in plasma in rats?

Jetté and colleagues (2005) reported presence in plasma beyond 72 hours in rats, with an albumin-associated species visible from 15 minutes to beyond 24 hours.

Is the no-DAC form just a weaker version?

No. It is a different tool. Its short action suits pulse and recovery designs that a long-acting molecule cannot support.

Which form does V8 list?

The product page lists CJC-1295 without DAC (Mod GRF 1-29) in 5 mg and 10 mg vials as a lyophilized powder, for laboratory research use only.

What did the knockout-mouse study show?

In GHRH knockout mice exposed for five weeks, once-daily CJC-1295 gave normal body weight and length, while less frequent administration was less effective, and pituitary GH mRNA increased (Alba and colleagues, 2006).

Why does pulsatile exposure matter?

In rats, pulsatile but not continuous infusion of GRF(1-29)NH2 promoted growth (Clark and Robinson, 1985), showing that exposure pattern shapes the response.

Does serum in cell culture matter for the DAC form?

Yes. Albumin in serum can bind the DAC molecule, so free concentration may differ from nominal concentration. Serum-free conditions are simpler to interpret.

Can the two forms be compared in one experiment?

Yes, if both are included as arms with matched molar concentration and the exposure schedule is specified, so that duration is the variable under study.

How is concentration calculated for either form?

Concentration equals the mass in the vial divided by the volume of diluent. Use the reconstitution calculator for the arithmetic.

Where can I see analytical documentation?

In the COA library where a certificate is published for the lot, and in the product page specifications.

Related reading: CJC-1295 DAC History: From GHRH to Albumin Conjugate, CJC-1295 DAC Mechanism of Action and Half-Life, CJC-1295 DAC Pharmacokinetics: Half-Life Explained.

References

  1. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
  2. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
  3. Frohman LA, Downs TR, Williams TC, Heimer EP, Pan YC, Felix AM. Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the N terminus. J Clin Invest. 1986;78(4):906-913. doi:10.1172/JCI112679
  4. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
  5. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-278. doi:10.1038/300276a0
  6. Clark RG, Robinson ICAF. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985;314(6008):281-283. doi:10.1038/314281a0
  7. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. doi:10.1210/edrv.19.6.0353

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.